Board of Directors
Chris is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund. Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies. Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry. Chris is a Director of BACE Therapeutics P/L, Fibrotech Therapeutics P/L Fluorotrop P/L, Global Kinetics Corporation P/L, Osprey Medical Inc., Polyactiva P/L and Spinifex Pharmaceuticals P/L. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne. Chris is a member of the Australian Institute of Company Directors and of AusBiotech.
Amanda is the Chief Operating Officer, Investments at BioScience Managers. Amanda is a life science investment professional at BioScience Managers where she plays a key role in deal origination, prospective investment due diligence, deal negotiation and portfolio management. Prior to BioScience Managers, Amanda was a Postdoctoral Fellow at Columbia University in New York City investigating molecular processes involved in intracellular trafficking. Amanda is currently a Director of SummatiX Pty Ltd, Rex Bionics Pty Ltd, Global Kinetics Corporation and a Board Observer for Canary Medical and Saluda Medical Pty Ltd. Amanda has a first class honours degree in Science and a PhD in Biochemistry from La Trobe University. She also has an MBA from Melbourne Business School.
Dr Lonngren has developed extensive experience in regulatory affairs in a career spanning almost 40 years. In his most prominent position he served as executive director of the European Medicine Agency for 10 years (2001-2010) where he was responsible for management of the agency and its scientific committees. Since his retirement from the EMA Dr Lonngren has worked as an independent consultant and advisor in health technology assessment and regulatory science for pharmaceutical companies and not-for-profit organisations. Dr Lonngren is also the strategy advisor to NDA Group, a EU leading regulatory and health technology assessment consulting firm.
Dr Read is the Acting Executive Chairman at GKC. Leighton is a US entrepreneur and investor with a track record of building companies commercialising medicines and life-science technologies. He was a managing director of Alloy Ventures and founded Affymax NV, where he served as President of the Pharma Division sold to GlaxoSmithKline, and spun out Affymetrix and Maxygen. Leighton was the founding investor, Chairman and CEO of Aviron which developed FluMist and has been a director of numerous companies and serves as a trustee and director of The BeneTech Initiative, BioVentures for Global Health and the UC Berkeley Foundation and School of Public Health Council. Leighton has won a number of awards in the field of life sciences and is based in San Francisco.
Based in New Hampshire, USA, John is a 33-year veteran of the Medical Device industry. Ten of those years were spent in senior expatriate assignments. Before becoming President and CEO of GKC, he served as President and CEO of Monteris Medical Corporation. Prior to joining Monteris, John served as the Chief Commercialization Officer for BÂRRX Medical, and as President and CEO of Softscope Medical Technologies Inc., both of which were successfully acquired by strategic partners during his tenure. John has held positions as Vice President of Sales and Marketing for the Peripheral Vascular Division of ev3 Inc., Vice President and General Manager International for ACMI Corporation, and various management positions within Boston Scientific. John earned a B.A, Summa Cum Laude, from Long Island University and, prior to his commercial career, he served 7 years as a U.S. Marine Corps pilot.
Greg Barrett became a member of our board of directors in March 2019. He has more than 35 years of medical device experience, working primarily in the fields of gastroenterology, urology, cardiology, gynecology and minimally invasive surgery. He was previously president and CEO at DFINE Inc, where he restructured the company and negotiated its sale to Merit Medical. Prior to DFINE, Greg was Chairman, President, and CEO of BÂRRX Medical, which was sold to Covidien in January 2012. Previous to joining BÂRRX Medical, Greg served as President and CEO of ACMI Corporation, which was acquired by Gyrus Medical and subsequently by Olympus Medical. Prior to ACMI, he was Group Vice President at Boston Scientific Corporation; Vice President, Global Sales and Marketing at both Orthofix Corporation (formerly American Medical Electronics) and Baxter Healthcare. Greg holds a B.A. in Marketing from the University of Texas.